BRPI0714179A2 - melhoramentos relacionados a composiÇÕes farmacÊuticas - Google Patents
melhoramentos relacionados a composiÇÕes farmacÊuticas Download PDFInfo
- Publication number
- BRPI0714179A2 BRPI0714179A2 BRPI0714179-3A BRPI0714179A BRPI0714179A2 BR PI0714179 A2 BRPI0714179 A2 BR PI0714179A2 BR PI0714179 A BRPI0714179 A BR PI0714179A BR PI0714179 A2 BRPI0714179 A2 BR PI0714179A2
- Authority
- BR
- Brazil
- Prior art keywords
- water
- sartan
- carrier
- solvent
- insoluble
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 239000002904 solvent Substances 0.000 claims abstract description 44
- 239000012876 carrier material Substances 0.000 claims abstract description 27
- 239000006185 dispersion Substances 0.000 claims abstract description 19
- 238000001694 spray drying Methods 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 82
- 239000002245 particle Substances 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 39
- 239000000839 emulsion Substances 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 29
- 239000004094 surface-active agent Substances 0.000 claims description 24
- 238000001035 drying Methods 0.000 claims description 23
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 17
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 17
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 17
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 17
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 17
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 17
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 16
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 16
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 16
- 239000003125 aqueous solvent Substances 0.000 claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 229920006187 aquazol Polymers 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 239000003096 antiparasitic agent Substances 0.000 claims description 2
- 239000012861 aquazol Substances 0.000 claims description 2
- 239000008365 aqueous carrier Substances 0.000 claims description 2
- 239000003093 cationic surfactant Substances 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 229940125687 antiparasitic agent Drugs 0.000 claims 1
- 239000000463 material Substances 0.000 description 29
- 239000000243 solution Substances 0.000 description 27
- 239000012071 phase Substances 0.000 description 23
- 239000000843 powder Substances 0.000 description 14
- -1 Candesartan Chemical compound 0.000 description 13
- 239000012153 distilled water Substances 0.000 description 13
- YOSHYTLCDANDAN-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2NN=NN=2)C(CCCC)=NC21CCCC2 YOSHYTLCDANDAN-UHFFFAOYSA-N 0.000 description 13
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 12
- 229960002198 irbesartan Drugs 0.000 description 12
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 description 11
- 239000002198 insoluble material Substances 0.000 description 11
- 239000004064 cosurfactant Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000007921 spray Substances 0.000 description 9
- 229960004699 valsartan Drugs 0.000 description 9
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 229960001701 chloroform Drugs 0.000 description 6
- 238000000265 homogenisation Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 229960000932 candesartan Drugs 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229910010272 inorganic material Inorganic materials 0.000 description 5
- 239000011147 inorganic material Substances 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000002083 C09CA01 - Losartan Substances 0.000 description 4
- 239000008118 PEG 6000 Substances 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 4
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 4
- 150000008052 alkyl sulfonates Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 229960004773 losartan Drugs 0.000 description 4
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000005862 Angiotensin II Human genes 0.000 description 3
- 101800000733 Angiotensin-2 Proteins 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000005480 Olmesartan Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 3
- 229950006323 angiotensin ii Drugs 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 229960005117 olmesartan Drugs 0.000 description 3
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 3
- 239000011368 organic material Substances 0.000 description 3
- 239000005022 packaging material Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920001992 poloxamer 407 Polymers 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000002195 soluble material Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- NZPSYYOURGWZCM-UHFFFAOYSA-N 2-butyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one;6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C2=NNN=N2)C(CCCC)=NC21CCCC2 NZPSYYOURGWZCM-UHFFFAOYSA-N 0.000 description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical class CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 2
- 229960004563 eprosartan Drugs 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- CPBQJMYROZQQJC-UHFFFAOYSA-N helium neon Chemical compound [He].[Ne] CPBQJMYROZQQJC-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010951 particle size reduction Methods 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000006104 solid solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical class OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 229940121792 Thiazide diuretic Drugs 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 125000005599 alkyl carboxylate group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 229940062309 avalide Drugs 0.000 description 1
- 229940000201 avapro Drugs 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 150000002193 fatty amides Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WUXWWSDWRUVSNE-UHFFFAOYSA-N methyl propane-1-sulfonate;prop-2-enamide Chemical class NC(=O)C=C.CCCS(=O)(=O)OC WUXWWSDWRUVSNE-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002717 polyvinylpyridine Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229920006301 statistical copolymer Polymers 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Wood Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Dentistry (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0613925.7A GB0613925D0 (en) | 2006-07-13 | 2006-07-13 | Improvements relating to nanodispersions |
| UK0613925.7 | 2006-07-13 | ||
| PCT/EP2007/056564 WO2008006716A2 (en) | 2006-07-13 | 2007-06-29 | Improvements relating to pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0714179A2 true BRPI0714179A2 (pt) | 2012-12-25 |
Family
ID=36955583
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0714179-3A BRPI0714179A2 (pt) | 2006-07-13 | 2007-06-29 | melhoramentos relacionados a composiÇÕes farmacÊuticas |
| BRPI0714176-9A BRPI0714176A2 (pt) | 2006-07-13 | 2007-06-29 | aperfeiÇoamentos relacionados À nanodispresço |
| BRPI0714177-7A BRPI0714177A2 (pt) | 2006-07-13 | 2007-06-29 | processo de preparo de composição biocida, composição biocida livre de solventes, dispersão aquosa, processo para o tratamento de um substrato, processo para a distribuição de um biocida e uso da composição |
| BRPI0714230-7A BRPI0714230A2 (pt) | 2006-07-13 | 2007-06-29 | melhoramentos relacionados a composiÇÕes farmacÊuticas |
| BRPI0722376-5A BRPI0722376A2 (pt) | 2006-07-13 | 2007-06-29 | composição fungicida livre de solventes, dispersão aquosa de um fungicida de estrobilurina, processo para preparar uma composição, processo para o tratamento de um substrato, processo para a entrega de um fungicida de estrobilurina, e, uso da composição |
| BRPI0714352-4A BRPI0714352A2 (pt) | 2006-07-13 | 2007-07-13 | processo para a produÇço de composiÇço, processo para a preparaÇço de um medicamento, composiÇço obtida pelo referido processo, uso de uma composiÇço, e, dispersço |
| BRPI0714351-6A BRPI0714351A2 (pt) | 2006-07-13 | 2007-07-13 | processo para produÇço de uma composiÇço opiàide, composiÇço compreendendo opiàide, uso de composiÇço compreendendo opiàide e dispersço compreendendo opiàide |
| BRPI0714353-2A BRPI0714353A2 (pt) | 2006-07-13 | 2007-07-13 | processos para a preparaÇço de composiÇÕes farmacÊuticas |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0714176-9A BRPI0714176A2 (pt) | 2006-07-13 | 2007-06-29 | aperfeiÇoamentos relacionados À nanodispresço |
| BRPI0714177-7A BRPI0714177A2 (pt) | 2006-07-13 | 2007-06-29 | processo de preparo de composição biocida, composição biocida livre de solventes, dispersão aquosa, processo para o tratamento de um substrato, processo para a distribuição de um biocida e uso da composição |
| BRPI0714230-7A BRPI0714230A2 (pt) | 2006-07-13 | 2007-06-29 | melhoramentos relacionados a composiÇÕes farmacÊuticas |
| BRPI0722376-5A BRPI0722376A2 (pt) | 2006-07-13 | 2007-06-29 | composição fungicida livre de solventes, dispersão aquosa de um fungicida de estrobilurina, processo para preparar uma composição, processo para o tratamento de um substrato, processo para a entrega de um fungicida de estrobilurina, e, uso da composição |
| BRPI0714352-4A BRPI0714352A2 (pt) | 2006-07-13 | 2007-07-13 | processo para a produÇço de composiÇço, processo para a preparaÇço de um medicamento, composiÇço obtida pelo referido processo, uso de uma composiÇço, e, dispersço |
| BRPI0714351-6A BRPI0714351A2 (pt) | 2006-07-13 | 2007-07-13 | processo para produÇço de uma composiÇço opiàide, composiÇço compreendendo opiàide, uso de composiÇço compreendendo opiàide e dispersço compreendendo opiàide |
| BRPI0714353-2A BRPI0714353A2 (pt) | 2006-07-13 | 2007-07-13 | processos para a preparaÇço de composiÇÕes farmacÊuticas |
Country Status (17)
| Country | Link |
|---|---|
| US (10) | US9060937B2 (enExample) |
| EP (8) | EP2040681B1 (enExample) |
| JP (9) | JP2009542760A (enExample) |
| CN (11) | CN101489535A (enExample) |
| AP (1) | AP2008004713A0 (enExample) |
| AR (4) | AR061992A1 (enExample) |
| AU (9) | AU2007271829B2 (enExample) |
| BR (8) | BRPI0714179A2 (enExample) |
| CA (8) | CA2659666A1 (enExample) |
| CL (4) | CL2007002031A1 (enExample) |
| ES (2) | ES2741124T3 (enExample) |
| GB (1) | GB0613925D0 (enExample) |
| IL (2) | IL195911A0 (enExample) |
| MX (2) | MX2009000309A (enExample) |
| TW (1) | TW200812694A (enExample) |
| WO (8) | WO2008006716A2 (enExample) |
| ZA (7) | ZA200900030B (enExample) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0501833D0 (en) * | 2005-01-28 | 2005-03-09 | Unilever Plc | Carrier liquids and methods of production thereof |
| WO2007133758A1 (en) * | 2006-05-15 | 2007-11-22 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
| GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
| WO2008022651A1 (en) | 2006-08-21 | 2008-02-28 | Antoine Turzi | Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells |
| AR063704A1 (es) | 2006-09-14 | 2009-02-11 | Makhteshim Chem Works Ltd | Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones |
| EP2124556B1 (en) | 2006-10-09 | 2014-09-03 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| EP2170313A2 (en) * | 2007-06-18 | 2010-04-07 | Combino Pharm, S.L. | Aqueous formulations of acetaminophen for injection |
| AR067047A1 (es) * | 2007-06-18 | 2009-09-30 | Combino Pharm Sl | Formulaciones acuosas de acetaminofen para inyeccion. |
| ES2731881T3 (es) | 2007-09-25 | 2019-11-19 | Formulex Pharma Innovations Ltd | Composiciones que comprenden compuestos activos lipófilos y método para su preparación |
| CA2905541C (en) | 2008-01-09 | 2020-02-11 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
| TR200800634A2 (tr) * | 2008-01-30 | 2009-02-23 | Takka Sevgi̇ | Uzatılmış salım sağlayan fluvastatin tablet. |
| US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| AU2009223061B2 (en) * | 2008-03-11 | 2014-10-09 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| US20110117157A1 (en) * | 2008-07-11 | 2011-05-19 | Nippon Soda Co., Ltd. | Method of manufacture of sustained-release formulation composition |
| GB0814953D0 (en) * | 2008-08-18 | 2008-09-24 | Unilever Plc | Improvements relating to nanodisperse compositions |
| CA2737452C (en) | 2008-09-25 | 2018-05-22 | Vive Nano Inc. | Methods to produce polymer nanoparticles and formulations of active ingredients |
| FR2938433B1 (fr) * | 2008-11-19 | 2011-09-09 | Francois Fauran | Compositions pharmaceutiques utilisant l'inuline comme excipient de granulation |
| WO2010082840A1 (en) * | 2008-12-12 | 2010-07-22 | Tim Tech Chemicals Limited | Compositions for the treatment of timber and other wood substrates |
| EP2243477A1 (de) * | 2009-04-22 | 2010-10-27 | Fresenius Kabi Deutschland GmbH | Paracetamol zur parenteralen Verabreichung |
| WO2010137888A2 (ko) * | 2009-05-27 | 2010-12-02 | 주식회사 삼양사 | 생체이용률이 향상된 난용성 약물 함유 미립구 및 그 제조 방법 |
| HUP0900376A2 (en) * | 2009-06-19 | 2011-01-28 | Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag | Nanoparticulate candesartan cilexetil composition |
| HUP0900384A2 (en) * | 2009-06-19 | 2011-01-28 | Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag | Nanoparticulate olmesartan medoxomil compositions |
| KR101817986B1 (ko) * | 2009-06-25 | 2018-01-16 | 진양제약주식회사 | 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법 |
| EP3311667A1 (en) | 2009-07-08 | 2018-04-25 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| KR20120059582A (ko) * | 2009-08-31 | 2012-06-08 | 데포메드 인코퍼레이티드 | 아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물 |
| JP5498769B2 (ja) * | 2009-12-04 | 2014-05-21 | 花王株式会社 | 脂溶性薬物内包ナノ粒子の製造方法 |
| US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
| US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
| SI2536396T1 (sl) | 2010-02-16 | 2017-01-31 | KRKA, tovarna zdravil, d.d.,Novo mesto | Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan |
| JP5602936B2 (ja) | 2010-03-29 | 2014-10-08 | フイルメニツヒ ソシエテ アノニム | 噴霧乾燥した結晶性活性成分 |
| GB201006038D0 (en) * | 2010-04-12 | 2010-05-26 | Unilever Plc | Improvements relating to antiviral compositions |
| UA111167C2 (uk) * | 2010-08-05 | 2016-04-11 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Пестицидні композиції мезорозмірних частинок з підсиленою дією |
| CN103249406A (zh) | 2010-10-05 | 2013-08-14 | 阿尔塔纳米产品有限公司 | 一种用于制备改进的组合物的方法 |
| US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
| US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
| WO2012082765A2 (en) | 2010-12-16 | 2012-06-21 | The United State Of America. As Represented By The Secretary Department Of Health And Human Services | Methods for decreasing body weight and treating diabetes |
| US8637038B2 (en) | 2011-04-12 | 2014-01-28 | Rigel Pharmaceuticals, Inc. | Methods for inhibiting allograft rejection |
| US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
| US8658631B1 (en) | 2011-05-17 | 2014-02-25 | Mallinckrodt Llc | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
| US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
| US9308190B2 (en) | 2011-06-06 | 2016-04-12 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
| JP2013001771A (ja) * | 2011-06-14 | 2013-01-07 | Neos Co Ltd | 液状カビ防除洗浄剤組成物 |
| RU2469536C1 (ru) * | 2011-06-16 | 2012-12-20 | Государственное бюджетное учреждение Республики Башкортостан "Научно-исследовательский технологический институт гербицидов и регуляторов роста растений с опытно-экспериментальным производством Академии наук Республики Башкортостан" | Фунгицидное средство и способ его получения |
| EA032840B8 (ru) | 2011-06-22 | 2020-06-18 | Вайоми Терапеутикс Лимитед | Пролекарства на основе конъюгатов противогрибковых агентов и их применение |
| CN104039140B (zh) | 2011-08-23 | 2017-07-21 | 维弗作物保护公司 | 拟除虫菊酯配制品 |
| GB201115079D0 (en) | 2011-08-31 | 2011-10-19 | Iota Nanosolutions Ltd | Method of preparing carrier liquids |
| GB201115633D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of efavirenz |
| GB201115635D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of lopinavir and ritonavir |
| GB201115634D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of lopinavir |
| US8609684B2 (en) | 2011-12-12 | 2013-12-17 | PruGen IP Holdings, Inc. | Solubilization and bioavailability of acetaminophen |
| EP2793574A4 (en) | 2011-12-22 | 2015-09-02 | Vive Crop Prot Inc | STROBILURINFORMULIERUNGEN |
| JP6247685B2 (ja) * | 2012-05-16 | 2017-12-13 | メワ・シン | 実質的に水不溶性の薬物の送達のための医薬組成物 |
| MX362838B (es) | 2012-07-12 | 2019-02-19 | SpecGx LLC | Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente. |
| US20140073678A1 (en) * | 2012-09-12 | 2014-03-13 | Monosol Rx, Llc | Anti-pain and anti-nausea and/or vomiting combinatorial compositions |
| HK1217409A1 (zh) | 2013-06-04 | 2017-01-13 | 维奥姆生物科学有限公司 | 涂布的颗粒和包括其的组合物 |
| AU2014306759B2 (en) | 2013-08-12 | 2018-04-26 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9925241B2 (en) | 2013-10-21 | 2018-03-27 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (FGF) 1 and methods of use |
| EP4173619A3 (en) * | 2013-11-13 | 2023-07-19 | National Defense Education and Research Foundation | New acetaminophen compound composition without side effect to liver |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| EP3119415A4 (en) | 2014-03-07 | 2017-11-29 | The Arizona Board of Regents on behalf of the University of Arizona | Non-narcotic crmp2 peptides targeting sodium channels for chronic pain |
| EP2952208A1 (en) * | 2014-06-04 | 2015-12-09 | Universidade de Santiago de Compostela | Hydroalcoholic system for nail treatment |
| AU2015275098B2 (en) | 2014-06-11 | 2018-12-06 | SpecGx LLC | Spray dried compositions having different dissolution profiles and processes for their preparation |
| CN104042626A (zh) * | 2014-07-01 | 2014-09-17 | 李绍明 | 杀菌抑菌剂 |
| WO2016010771A1 (en) | 2014-07-17 | 2016-01-21 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| CA2964628A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| JP2018502742A (ja) * | 2014-12-23 | 2018-02-01 | ダウ グローバル テクノロジーズ エルエルシー | 処理済み多孔質材料 |
| JP6730315B2 (ja) * | 2015-01-20 | 2020-07-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 担体ポリマーとしてのポリビニルアルコールを用いた化合物の固体分散体 |
| CN104798772B (zh) * | 2015-03-13 | 2017-05-24 | 中国农业科学院农业环境与可持续发展研究所 | 一种农药纳米固体分散体及其制备方法 |
| US10034857B2 (en) | 2015-07-02 | 2018-07-31 | Civitas Therapeutics, Inc. | Triptan powders for pulmonary delivery |
| EP3324959B1 (en) | 2015-07-17 | 2023-07-12 | The Board Of Regents Of The University Of Oklahoma | Licofelone derivatives and methods of use |
| CN105145553A (zh) * | 2015-10-12 | 2015-12-16 | 广西田园生化股份有限公司 | 一种难溶农药的固体分散体组合物 |
| ES2812155T3 (es) * | 2016-02-02 | 2021-03-16 | Evonik Operations Gmbh | Formulaciones pulverulentas de sustancias tensioactivas sobre soportes sólidos hidrosolubles, procedimientos para su producción, así como su empleo |
| WO2017152130A1 (en) | 2016-03-04 | 2017-09-08 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| CA3027817C (en) * | 2016-06-16 | 2023-12-19 | The University Of Liverpool | Chemical composition for the treatment and prophylaxis of systemic infections |
| RU2619249C1 (ru) * | 2016-11-07 | 2017-05-12 | Федеральное государственное бюджетное учреждение науки Институт химии твердого тела и механохимии Сибирского отделения Российской академии наук (ИХТТМ СО РАН) | Композиция для протравливания семян и способ её получения |
| WO2018160772A1 (en) | 2017-02-28 | 2018-09-07 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis |
| EP3601301A1 (en) | 2017-03-31 | 2020-02-05 | The University of Liverpool | Prodrug compositions |
| US20210015752A1 (en) * | 2017-06-15 | 2021-01-21 | Savior Lifetec Corporation | Methods for producing particles of an active ingredient |
| US11517013B2 (en) | 2017-08-25 | 2022-12-06 | Vive Crop Protection Inc. | Multi-component, soil-applied, pesticidal compositions |
| US20210361639A1 (en) | 2018-03-02 | 2021-11-25 | The University Of Liverpool | Solid compositions of actives, processes for preparing same and uses of such solid compositions |
| JP6858729B2 (ja) * | 2018-05-25 | 2021-04-14 | ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成 |
| US20210346462A1 (en) | 2018-10-04 | 2021-11-11 | Rutgers, The State University Of New Jersey | Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides |
| WO2020135600A1 (zh) * | 2018-12-28 | 2020-07-02 | 南京善思生物科技有限公司 | 纳米农药制剂及其制备方法 |
| CN109846821B (zh) * | 2019-01-03 | 2021-07-06 | 昆药集团股份有限公司 | 一种蒿甲醚纳米制剂及其制备方法 |
| US20220054494A1 (en) | 2019-03-13 | 2022-02-24 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods for treating bladder and urethra dysfunction and disease |
| CN110074993A (zh) * | 2019-06-05 | 2019-08-02 | 山东大学 | 一种制备紫外吸收剂纳米颗粒的方法 |
| MX2021015576A (es) * | 2019-06-28 | 2022-03-02 | Solstar Pharma | Formulacion gastroretentiva de liberacion extendida contra helicobacter pylori. |
| WO2021062012A1 (en) | 2019-09-25 | 2021-04-01 | Emory University | Use of klk10 and engineered derivatizations thereof |
| CN114615889A (zh) * | 2019-10-28 | 2022-06-10 | 组合化学工业株式会社 | 农药组合物及其制造方法 |
| CA3165922A1 (en) | 2020-01-17 | 2021-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Gene therapy for treatment of crx-autosomal dominant retinopathies |
| US20230181672A1 (en) | 2020-05-07 | 2023-06-15 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms |
| IT202000022789A1 (it) | 2020-09-28 | 2020-12-28 | Vitop Moulding Srl | Rubinetto erogatore provvisto di sistema di collocamento, bloccaggio e orientamento su scatole di tipo Bag-In-Box |
| GB202115049D0 (en) | 2021-10-20 | 2021-12-01 | Univ Liverpool | Chemical Compositions |
| WO2023196898A1 (en) | 2022-04-07 | 2023-10-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Beta globin mimetic peptides and their use |
| CN114732009B (zh) * | 2022-06-13 | 2022-08-23 | 山东百农思达生物科技有限公司 | 一种含有吡唑醚菌酯和烯酰吗啉的水分散粒剂的制备方法 |
| AU2024240009A1 (en) | 2023-03-17 | 2025-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for treatment of age-related macular degeneration |
| GB202304657D0 (en) | 2023-03-29 | 2023-05-10 | Univ Liverpool | Atovaquine compositions |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB501835A (en) | 1936-05-29 | 1939-03-02 | Siemens Ag | Process and apparatus for reducing the power required for the mechanical treatment of movable masses |
| GB1305024A (enExample) * | 1969-07-10 | 1973-01-31 | ||
| GB1554662A (en) * | 1976-05-05 | 1979-10-24 | Inverni Della Beffa Spa | Polyhydroxyphenylchromanones |
| US4230687A (en) * | 1978-05-30 | 1980-10-28 | Griffith Laboratories U.S.A., Inc. | Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices |
| DE3439482A1 (de) * | 1984-10-27 | 1986-05-07 | Röhm GmbH, 6100 Darmstadt | Verfahren zur beschichtung von substraten mit kratzfesten, nichtreflektierenden ueberzuegen |
| US4830858A (en) * | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
| US5160530A (en) * | 1989-01-24 | 1992-11-03 | Griffin Corporation | Microencapsulated polymorphic agriculturally active material |
| GB8918807D0 (en) * | 1989-08-17 | 1989-09-27 | Shell Int Research | A solid pesticidal formulation,a process for its preparation and the use thereof |
| JP3067810B2 (ja) * | 1990-12-21 | 2000-07-24 | 中外製薬株式会社 | 経口投与用ｏ／ｗ型エマルジョンの乾燥粉末製造法 |
| GB9304294D0 (en) * | 1993-03-03 | 1993-04-21 | Zeneca Ltd | Herbicidal compositions |
| DE4329446A1 (de) * | 1993-09-01 | 1995-03-02 | Basf Ag | Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen |
| US5858398A (en) * | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
| TW318777B (enExample) * | 1995-06-29 | 1997-11-01 | Novartis Ag | |
| EP0862420A4 (en) | 1995-10-13 | 1999-11-03 | Penn State Res Found | SYNTHESIS OF DRUG SPRAY DRUG NANOPARTICLES |
| GB9606188D0 (en) * | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
| US5858409A (en) | 1996-04-17 | 1999-01-12 | Fmc Corporation | Hydrolyzed cellulose granulations for pharmaceuticals |
| US5976574A (en) | 1996-12-31 | 1999-11-02 | Inhale Therapeutic Systems | Processes for spray drying hydrophobic drugs in organic solvent suspensions |
| JP4183279B2 (ja) * | 1997-04-15 | 2008-11-19 | アール ピー シェーラー テクノロジーズ インコーポレーテッド | 医薬用加水分解セルロース顆粒 |
| EP1080720A4 (en) * | 1998-03-05 | 2002-06-05 | Nippon Shinyaku Co Ltd | FAT EMULSIONS FOR INHALATIVE ADMINISTRATION |
| JPH11322587A (ja) | 1998-05-18 | 1999-11-24 | Sumitomo Chem Co Ltd | 常温で固体の生理活性物質のマイクロカプセル化方法およびこの方法により得られるマイクロカプセル組成物 |
| WO2000040220A1 (en) * | 1999-01-06 | 2000-07-13 | Korea Research Institute Of Chemical Technology | Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same |
| EP1027886B1 (en) * | 1999-02-10 | 2008-07-09 | Pfizer Products Inc. | Pharmaceutical solid dispersions |
| GB9904012D0 (en) | 1999-02-22 | 1999-04-14 | Zeneca Ltd | Agrochemical formulation |
| US6610317B2 (en) | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
| IL146659A0 (en) * | 1999-05-27 | 2002-07-25 | Acusphere Inc | Porous drug matrices and method of manufacture thereof |
| US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| GB9915231D0 (en) | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
| GB9920148D0 (en) * | 1999-08-25 | 1999-10-27 | Smithkline Beecham Plc | Novel composition |
| CA2392810A1 (en) | 1999-12-01 | 2001-06-07 | Natco Pharma Limited | A rapid acting freeze dired oral pharmaceutical composition for treating migraine |
| KR100694667B1 (ko) * | 1999-12-08 | 2007-03-14 | 동아제약주식회사 | 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제 |
| US6207674B1 (en) * | 1999-12-22 | 2001-03-27 | Richard A. Smith | Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
| US20020044969A1 (en) | 2000-05-22 | 2002-04-18 | Jerome Harden | Method for increasing the compressibility of poorly binding powder materials |
| US6932963B2 (en) * | 2000-06-23 | 2005-08-23 | Nicholas V. Perricone | Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines |
| IT1318618B1 (it) | 2000-07-10 | 2003-08-27 | A C R Applied Coating Res S A | Microsfere bioadesive a rilascio rapido per la somministrazionesublinguale di principi attivi. |
| CA2416600A1 (en) * | 2000-07-24 | 2003-01-20 | Ono Pharmaceutical Co., Ltd. | Freeze-dried preparation of n-¬o-(p-pivaloyloxybenzenesulfonylamino)benzoyl|glycine monosodium salt tetrahydrate and a process for the maufacture thereof |
| DE10036871A1 (de) * | 2000-07-28 | 2002-02-14 | Pharmasol Gmbh | Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe |
| EP1322289B1 (en) * | 2000-09-20 | 2007-07-25 | Jagotec AG | Spray drying process of compositions containing fenofibrate |
| US6756062B2 (en) * | 2000-11-03 | 2004-06-29 | Board Of Regents University Of Texas System | Preparation of drug particles using evaporation precipitation into aqueous solutions |
| US8067032B2 (en) * | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
| US6862890B2 (en) * | 2001-01-30 | 2005-03-08 | Board Of Regents, University Of Texas System | Process for production of nanoparticles and microparticles by spray freezing into liquid |
| US6355675B1 (en) | 2001-05-15 | 2002-03-12 | Isp Investments Inc. | Emulsifiable concentrate of a water-insoluble fungicide |
| MXPA03011017A (es) * | 2001-06-01 | 2005-04-29 | Pozen Inc | Composiciones farmaceuticas para la entrega coordinada de nsaids. |
| ATE480226T1 (de) * | 2001-06-22 | 2010-09-15 | Bend Res Inc | Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere |
| KR100425226B1 (ko) * | 2001-07-03 | 2004-03-30 | 주식회사 팜트리 | 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법 |
| WO2003017659A1 (fr) * | 2001-08-21 | 2003-02-27 | Sony Corporation | Systeme de traitement de donnees, dispositif et procede de traitement de donnees |
| US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
| WO2003026611A2 (en) | 2001-09-26 | 2003-04-03 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
| DE10151392A1 (de) * | 2001-10-18 | 2003-05-08 | Bayer Cropscience Ag | Pulverförmige Feststoff-Formulierungen |
| US20040242427A1 (en) * | 2001-11-07 | 2004-12-02 | Sebastian Koltzenburg | Cinidon-ethyl containing solid crop protection formulations and corresponding dispersions |
| DE60211029T2 (de) * | 2001-11-07 | 2006-08-31 | Basf Ag | Nanopartikel enthaltend ein pflanzenschutzmittel |
| WO2003063822A2 (en) * | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| JP2005522424A (ja) * | 2002-02-01 | 2005-07-28 | ファイザー・プロダクツ・インク | コレステリルエステル転移タンパク質インヒビターの制御放出性薬剤投与形態 |
| US6780324B2 (en) * | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
| US20040028505A1 (en) * | 2002-06-07 | 2004-02-12 | Bilbrey Robert A. | Document tape binding system with automatic tape feed, tape indicia sensing, spine printing method and post-bind automation mechanisms |
| CA2488499C (en) | 2002-06-10 | 2013-03-19 | Elan Pharma International Ltd. | Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions |
| US20030017208A1 (en) * | 2002-07-19 | 2003-01-23 | Francis Ignatious | Electrospun pharmaceutical compositions |
| DE10244681A1 (de) * | 2002-09-24 | 2004-04-08 | Boehringer Ingelheim International Gmbh | Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung |
| JP2006501936A (ja) * | 2002-10-04 | 2006-01-19 | エラン ファーマ インターナショナル，リミティド | 固体ナノ粒子活性薬剤のガンマ線照射 |
| CN1176649C (zh) | 2002-10-16 | 2004-11-24 | 上海医药工业研究院 | 舒马普坦干粉吸入剂及其制备方法 |
| US20040220081A1 (en) * | 2002-10-30 | 2004-11-04 | Spherics, Inc. | Nanoparticulate bioactive agents |
| EP1575566B1 (en) * | 2002-12-26 | 2012-02-22 | Pozen, Inc. | Multilayer dosage forms containing naproxen and triptans |
| JP2006520746A (ja) * | 2002-12-27 | 2006-09-14 | カイロン コーポレイション | リン脂質を含む免疫原性組成物 |
| AU2004206109A1 (en) * | 2003-01-21 | 2004-08-05 | Ranbaxy Laboratories Limited | Co-precipitated amorphous losartan and dosage forms comprising the same |
| US20040197301A1 (en) * | 2003-02-18 | 2004-10-07 | Zhong Zhao | Hybrid polymers and methods of making the same |
| CA2514875A1 (en) * | 2003-02-19 | 2004-09-02 | Biovail Laboratories International Srl | Rapid absorption selective 5-ht agonist formulations |
| WO2004075921A1 (en) * | 2003-02-26 | 2004-09-10 | Vrije Universiteit Brussel | Inclusion complex of artemisinin or derivates thereof with cyclodextrins |
| MXPA05010821A (es) | 2003-04-08 | 2006-03-30 | Progenics Pharm Inc | Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico. |
| US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| CA2465565A1 (en) | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| CA2532450C (en) * | 2003-07-16 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Chlorthalidone combinations |
| US7687167B2 (en) * | 2003-07-18 | 2010-03-30 | Panasonic Corporation | Power supply unit |
| CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| DE10338403A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum |
| DE10351004A1 (de) * | 2003-10-30 | 2005-05-25 | Basf Ag | Nanopartikuläre Wirkstoffformulierungen |
| DE10351087A1 (de) * | 2003-10-31 | 2005-05-25 | Bayer Technology Services Gmbh | Feste Wirkstoff-Formulierung |
| KR100603974B1 (ko) * | 2003-12-05 | 2006-07-25 | 김갑식 | 고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법 |
| JP2007517015A (ja) * | 2003-12-31 | 2007-06-28 | ファイザー・プロダクツ・インク | 低溶解性薬物、ポロキサマーおよび安定化ポリマーの安定化された医薬用固体組成物 |
| KR100629771B1 (ko) * | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법 |
| IL160095A0 (en) | 2004-01-28 | 2004-06-20 | Yissum Res Dev Co | Formulations for poorly soluble drugs |
| JP2005298347A (ja) * | 2004-04-06 | 2005-10-27 | Yoshiaki Kawashima | 吸入製剤及びその製造方法 |
| KR100598326B1 (ko) * | 2004-04-10 | 2006-07-10 | 한미약품 주식회사 | ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법 |
| RU2006141846A (ru) * | 2004-04-28 | 2008-06-10 | Юнилевер Н.В. (Nl) | Пищевое масло, содержащее статины |
| WO2005117834A1 (en) * | 2004-05-27 | 2005-12-15 | Janssen Pharmaceutica N.V. | Solid dispersions of a basic drug compound and a polymer containing acidic groups |
| DK1641438T3 (da) | 2004-06-01 | 2010-06-07 | Teva Gyogyszergyar Zartkoeruen | Fremgangsmåde til fremstilling af den amorfe form af et lægemiddel |
| DE102004031298A1 (de) | 2004-06-28 | 2006-01-12 | Basf Ag | Wässrige Dispersionen schwer wasserlöslicher oder wasserunlöslicher Wirkstoffe und daraus hergestellte Trockenpulver enthaltend mindestens ein Polyethergruppen enthaltendes Polymer als Schutzkolloid |
| WO2006038552A1 (ja) * | 2004-10-01 | 2006-04-13 | Eisai R & D Management Co., Ltd. | 微粒子含有組成物およびその製造方法 |
| US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
| CN101132770A (zh) * | 2005-01-06 | 2008-02-27 | 伊兰制药国际有限公司 | 纳米微粒坎地沙坦制剂 |
| GB0501835D0 (en) * | 2005-01-28 | 2005-03-09 | Unilever Plc | Improvements relating to spray dried compositions |
| GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
| WO2008076780A2 (en) * | 2006-12-14 | 2008-06-26 | Isp Investments Inc. | Amorphous valsartan and the production thereof |
-
2006
- 2006-07-13 GB GBGB0613925.7A patent/GB0613925D0/en not_active Ceased
-
2007
- 2007-06-29 EP EP07786933.7A patent/EP2040681B1/en active Active
- 2007-06-29 CN CNA2007800263679A patent/CN101489535A/zh active Pending
- 2007-06-29 WO PCT/EP2007/056564 patent/WO2008006716A2/en not_active Ceased
- 2007-06-29 US US12/309,292 patent/US9060937B2/en active Active
- 2007-06-29 EP EP07786931A patent/EP2040679A2/en not_active Ceased
- 2007-06-29 CA CA002659666A patent/CA2659666A1/en not_active Abandoned
- 2007-06-29 JP JP2009518831A patent/JP2009542760A/ja active Pending
- 2007-06-29 AU AU2007271829A patent/AU2007271829B2/en not_active Ceased
- 2007-06-29 US US12/309,293 patent/US20090239749A1/en not_active Abandoned
- 2007-06-29 CN CN201010193750A patent/CN101849911A/zh active Pending
- 2007-06-29 CA CA002656223A patent/CA2656223A1/en not_active Abandoned
- 2007-06-29 BR BRPI0714179-3A patent/BRPI0714179A2/pt not_active IP Right Cessation
- 2007-06-29 CN CNA2007800262657A patent/CN101489532A/zh active Pending
- 2007-06-29 BR BRPI0714176-9A patent/BRPI0714176A2/pt not_active IP Right Cessation
- 2007-06-29 AU AU2007271827A patent/AU2007271827B2/en not_active Ceased
- 2007-06-29 MX MX2009000309A patent/MX2009000309A/es not_active Application Discontinuation
- 2007-06-29 US US12/309,295 patent/US20100015233A1/en not_active Abandoned
- 2007-06-29 JP JP2009518832A patent/JP2009542761A/ja active Pending
- 2007-06-29 EP EP07765733.6A patent/EP2040677B1/en active Active
- 2007-06-29 ES ES07765733T patent/ES2741124T3/es active Active
- 2007-06-29 WO PCT/EP2007/056562 patent/WO2008006714A2/en not_active Ceased
- 2007-06-29 JP JP2009518835A patent/JP2009542764A/ja active Pending
- 2007-06-29 EP EP20100175541 patent/EP2269581A1/en not_active Withdrawn
- 2007-06-29 ZA ZA200900030A patent/ZA200900030B/xx unknown
- 2007-06-29 ES ES07786932T patent/ES2752460T3/es active Active
- 2007-06-29 AU AU2007271828A patent/AU2007271828B2/en not_active Ceased
- 2007-06-29 CA CA002656217A patent/CA2656217A1/en not_active Abandoned
- 2007-06-29 CN CNA2007800262750A patent/CN101489533A/zh active Pending
- 2007-06-29 CA CA002656233A patent/CA2656233A1/en not_active Abandoned
- 2007-06-29 CN CN2012101088434A patent/CN102631874A/zh active Pending
- 2007-06-29 CN CNA2007800263575A patent/CN101489534A/zh active Pending
- 2007-06-29 ZA ZA200900031A patent/ZA200900031B/xx unknown
- 2007-06-29 CA CA2656229A patent/CA2656229C/en active Active
- 2007-06-29 WO PCT/EP2007/056563 patent/WO2008006715A2/en not_active Ceased
- 2007-06-29 AU AU2007271831A patent/AU2007271831B2/en not_active Ceased
- 2007-06-29 JP JP2009518834A patent/JP2009542763A/ja active Pending
- 2007-06-29 US US12/309,306 patent/US20090175953A1/en not_active Abandoned
- 2007-06-29 CN CNA2007800262267A patent/CN101489531A/zh active Pending
- 2007-06-29 ZA ZA200900028A patent/ZA200900028B/xx unknown
- 2007-06-29 AU AU2007271830A patent/AU2007271830B2/en not_active Ceased
- 2007-06-29 AP AP2008004713A patent/AP2008004713A0/xx unknown
- 2007-06-29 US US12/309,294 patent/US8821932B2/en active Active
- 2007-06-29 EP EP11005053A patent/EP2387992A1/en not_active Ceased
- 2007-06-29 BR BRPI0714177-7A patent/BRPI0714177A2/pt not_active IP Right Cessation
- 2007-06-29 BR BRPI0714230-7A patent/BRPI0714230A2/pt not_active IP Right Cessation
- 2007-06-29 MX MX2009000307A patent/MX2009000307A/es not_active Application Discontinuation
- 2007-06-29 EP EP07786932.9A patent/EP2040680B1/en active Active
- 2007-06-29 EP EP07765734A patent/EP2040678A2/en not_active Withdrawn
- 2007-06-29 EP EP11005052A patent/EP2386292A1/en active Pending
- 2007-06-29 CN CN2012101088167A patent/CN102671585A/zh active Pending
- 2007-06-29 WO PCT/EP2007/056560 patent/WO2008006712A2/en not_active Ceased
- 2007-06-29 JP JP2009518833A patent/JP2009542762A/ja active Pending
- 2007-06-29 ZA ZA200900027A patent/ZA200900027B/xx unknown
- 2007-06-29 ZA ZA200900029A patent/ZA200900029B/xx unknown
- 2007-06-29 BR BRPI0722376-5A patent/BRPI0722376A2/pt not_active IP Right Cessation
- 2007-06-29 WO PCT/EP2007/056561 patent/WO2008006713A2/en not_active Ceased
- 2007-07-11 TW TW096125298A patent/TW200812694A/zh unknown
- 2007-07-12 CL CL2007002031A patent/CL2007002031A1/es unknown
- 2007-07-12 CL CL2007002030A patent/CL2007002030A1/es unknown
- 2007-07-12 CL CL2007002032A patent/CL2007002032A1/es unknown
- 2007-07-13 JP JP2009518979A patent/JP2009542794A/ja active Pending
- 2007-07-13 CN CNA2007800338285A patent/CN101516340A/zh active Pending
- 2007-07-13 CA CA002657548A patent/CA2657548A1/en not_active Abandoned
- 2007-07-13 AU AU2007274039A patent/AU2007274039A1/en not_active Abandoned
- 2007-07-13 AR ARP070103118A patent/AR061992A1/es not_active Application Discontinuation
- 2007-07-13 AU AU2007274041A patent/AU2007274041A1/en not_active Abandoned
- 2007-07-13 ZA ZA200900345A patent/ZA200900345B/xx unknown
- 2007-07-13 BR BRPI0714352-4A patent/BRPI0714352A2/pt not_active IP Right Cessation
- 2007-07-13 CN CNA2007800338444A patent/CN101516341A/zh active Pending
- 2007-07-13 AR ARP070103117A patent/AR061991A1/es not_active Application Discontinuation
- 2007-07-13 BR BRPI0714351-6A patent/BRPI0714351A2/pt not_active IP Right Cessation
- 2007-07-13 US US12/309,343 patent/US20100008995A1/en not_active Abandoned
- 2007-07-13 US US12/309,344 patent/US8945626B2/en not_active Expired - Fee Related
- 2007-07-13 JP JP2009518980A patent/JP2009542795A/ja active Pending
- 2007-07-13 ZA ZA200900347A patent/ZA200900347B/xx unknown
- 2007-07-13 WO PCT/GB2007/050408 patent/WO2008007151A2/en not_active Ceased
- 2007-07-13 JP JP2009518978A patent/JP2009542793A/ja active Pending
- 2007-07-13 WO PCT/GB2007/050409 patent/WO2008007152A2/en not_active Ceased
- 2007-07-13 AR ARP070103116A patent/AR061990A1/es not_active Application Discontinuation
- 2007-07-13 WO PCT/GB2007/050407 patent/WO2008007150A1/en not_active Ceased
- 2007-07-13 CA CA002657582A patent/CA2657582A1/en not_active Abandoned
- 2007-07-13 AU AU2007274040A patent/AU2007274040A1/en not_active Abandoned
- 2007-07-13 CA CA002657586A patent/CA2657586A1/en not_active Abandoned
- 2007-07-13 CN CNA2007800338942A patent/CN101516342A/zh active Pending
- 2007-07-13 US US12/309,341 patent/US7691873B2/en not_active Expired - Fee Related
- 2007-07-13 BR BRPI0714353-2A patent/BRPI0714353A2/pt not_active Application Discontinuation
-
2008
- 2008-12-11 IL IL195911A patent/IL195911A0/en unknown
- 2008-12-15 IL IL195933A patent/IL195933A/en not_active IP Right Cessation
-
2010
- 2010-05-11 AU AU2010201900A patent/AU2010201900A1/en not_active Abandoned
- 2010-05-19 CL CL2010000516A patent/CL2010000516A1/es unknown
- 2010-06-08 JP JP2010131047A patent/JP2010202665A/ja not_active Withdrawn
- 2010-06-23 AR ARP100102205A patent/AR077195A2/es not_active Application Discontinuation
-
2012
- 2012-02-03 US US13/365,830 patent/US20120135058A1/en not_active Abandoned
- 2012-02-03 US US13/365,826 patent/US20120134940A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0714179A2 (pt) | melhoramentos relacionados a composiÇÕes farmacÊuticas | |
| Shi et al. | Recent advances in enhancement of dissolution and supersaturation of poorly water-soluble drug in amorphous pharmaceutical solids: A review | |
| CA2735698A1 (en) | Improvements relating to pharmaceutical compositions | |
| BRPI0714175A2 (pt) | melhorias relacionadas a composiÇÕes anti-parasitÁrias | |
| US20190008790A1 (en) | A method for the preparation of a delivery drug delivery system and a composition therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 6A. ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2231 DE 08/10/2013. |